HTG Molecular Diagnostics and QIAGEN Team Up to Advance Precision Diagnostics

TUCSON, Ariz., and VENLO, the Netherlands, Nov. 16, 2016 -- HTG Molecular Diagnostics, Inc. (HTGM) (“HTG”), a provider of instruments and reagents for molecular profiling applications and QIAGEN Manchester Limited, a wholly owned subsidiary of QIAGEN N.V. (QGEN) (Frankfurt Stock Exchange:QIA); “QIAGEN”), announced a Master Assay Development, Commercialization and Manufacturing Agreement (“Agreement”).  This Agreement creates a framework for both companies to combine their technological and commercial strengths with the goal to offer pharmaceutical companies a complete NGS-based solution for the development and commercialization of companion diagnostics, with a focus in oncology.  Together with the parties’ entry into the Agreement, QIAGEN North American Holdings, Inc., another QIAGEN subsidiary, made a minority investment in HTG’s common stock.

“We are very impressed with QIAGEN’s Sample to Insight philosophy and quickly envisioned development and commercial synergies through our combined efforts with pharma,” said TJ Johnson, HTG’s President and Chief Executive Officer.  “Our objective is to develop a complete NGS solution from biomarker discovery to commercialized companion diagnostics and we believe this agreement accelerates both companies’ efforts. We are excited to offer this solution to customers,” added Mr. Johnson.

 

“HTG’s extraction free technology can add attractive capabilities to QIAGEN’s NGS‑based Sample to Insight solutions for applications in pathology where sample often is limited,” said Kai te Kaat, Vice President, Head of Franchise Oncology, Molecular Diagnostics Business Area at QIAGEN. “The addition of HTG’s technology to our Sample to Insight GeneReader NGS system, and augmented by QIAGEN’s capabilities across NGS workflows, will enable our pharma partners to successfully profile patients including settings where only low sample amounts are available. This capability is of interest in many indication areas but primarily in oncology and immune-oncology applications.”

 

About HTG:

 

Headquartered in Tucson, Arizona, HTG’s mission is to empower precision medicine at the local level. In 2013, the company commercialized its HTG Edge instrument platform and a portfolio of RNA assays that leverage HTG’s proprietary nuclease protection chemistry. HTG’s product offerings have since expanded to include its HTG EdgeSeq product line, which automates sample and targeted library preparation for next-generation sequencing. Additional information is available at www.htgmolecular.com.

 

HTG Safe Harbor Statement: 

 

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the anticipated benefits of our agreement with QIAGEN Manchester Limited, and our ability to successfully develop next-generation sequencing (NSG)-based solutions for biomarker discovery through commercialized companion diagnostics, and support the development, regulatory filing and commercialization of companion diagnostics. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential,” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based upon management’s current expectations, are subject to known and unknown risks, and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation, the risk that we may not realize the expected benefits from our agreement with QIAGEN Manchester Limited, risks associated with the utility of our automation systems, proprietary profiling panels and solutions, and our ability to successfully manufacture and supply our products. These and other factors are described in greater detail in our filings with the Securities and Exchange Commission, including, without limitation, our Quarterly Report on Form 10-Q for the quarter ended September 30, 2016. All forward-looking statements contained in this press release speak only as of the date on which they were made, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

 

HTG Contacts:  

Westwicke Partners

Jamar Ismail

Phone: 415-513-1282

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

 

TJ Johnson

President / CEO

HTG Molecular Diagnostics

Phone: 520-547-2827 x130

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

 

About QIAGEN:

 

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharma and biotech companies) and Academia (life sciences research). As of September 30, 2016, QIAGEN employed approximately 4,700 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.

 

QIAGEN Contacts:

Investor Relations:

John Gilardi

Vice President Corporate Communications and Investor Relations

+49 2103 29 11711

+1 240 686 2222

 

Dr. Sarah Fakih

Associate Director Investor Relations

+49 2103 29 11457

 

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

ir.qiagen.com

 

Public Relations:

Dr. Thomas Theuringer

Senior Director Public Relations and Digital Communications

+49 2103 29 11826

+1 240 686 7425

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

 

www.twitter.com/qiagen

www.facebook.com/QIAGEN

pr.qiagen.com